<DOC>
	<DOCNO>NCT00916032</DOCNO>
	<brief_summary>The objective clinical study compare pharmacokinetic parameter 3000 IU Advate use one 3000 IU potency vial dissolve 5 mL diluent 3000 IU Advate use two vial 1500 IU potency dissolve 5 mL diluent ( administer 10 mL diluent total ) previously treat patient severe hemophilia A ( factor VIII level &lt; 1 % ) .</brief_summary>
	<brief_title>Pharmacokinetic Study ADVATE 3000 IU Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Participant 18 65 year old , time screen Participant provide sign informed consent Participant severe hemophilia A , defined baseline FVIII level &lt; 1 % normal , test screening central laboratory Participant 's weight 5565 kg Participant previously treat FVIII concentrate ( ) minimum 150 exposure day prior study entry If Participant HIV positive , must immunocompetent determined CD4 count ≥ 200 cells/mm³ ( CD4 count screen ) Participant willing able comply requirement protocol Participant detectable FVIII inhibitor screening , titer ≥ 0.4 Bethesda unit ( BU ) ( Nijmegen modification Bethesda Assay ) measure central laboratory Participant history FVIII inhibitor titer ≥ 0.4 BU ( Nijmegen assay ) ≥ 0.5 BU ( Bethesda Assay ) time prior screen Participant undergone surgery within 21 day prior screen within 6 week prior anticipate first pharmacokinetics ( PK ) infusion Participant abnormal renal function ( serum creatinine &gt; 1.5 mg/dL ) Participant active hepatic disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 5 time upper limit normal ) Participant severe chronic liver disease evidence , limited , follow : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly , history esophageal varix Participant clinical and/or laboratory evidence abnormal hemostasis cause hemophilia A ( eg , latestage chronic liver disease , immune thrombocytopenia purpura ) Participant currently receive , schedule receive course clinical study , immunomodulating drug antiretroviral chemotherapy ( eg , alfainterferon , corticosteroid agent dose equivalent hydrocortisone great 10 mg/day ) Participant know hypersensitivity mouse hamster proteins Participant participate another clinical study involve investigational product investigational device within 30 day prior enrollment schedule participate another clinical study involve investigational product investigational device course clinical study Participant identify investigator unable unwilling cooperate study procedure Participant member team conduct clinical study dependent relationship one study team member . Dependent relationship include close relative ( ie , child , partner/spouse , sibling , parent ) well employee investigator site personnel conduct clinical study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>